ClinicalTrials.gg
CompletedNCT03104699Updated Jul 30, 2025Results posted

A Study of AGEN2034 in Advanced Tumors and Cervical Cancer

A Phase 1/2 interventional study of AGEN2034 in Advanced Cancer and Cervical Cancer, sponsored by Agenus Inc.. Completed at 44 sites in 9 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-30.

Sponsored by Agenus Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
211
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 834 studies in Uterine Cervical Neoplasms with a site in United States — 145 open to participants now, 219 under way, 6 of them phase 3. Uterine Cervical Neoplasms · United States.

Enrollment
183rd of 678
211 · median 71
Started
2017
with 25 others
Phase 1/2
74 of 834
23 open now
Registered
429th of 834
by date

Among the 834 studies in Uterine Cervical Neoplasms with a site in United States, this one is the 183rd largest by enrollment of the 678 interventional ones that give a count, is one of 26 that started in 2017, is one of 74 in phase 1/2, and was the 429th registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 677 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

145 of the 834 studies in Uterine Cervical Neoplasms with a site in United States are open now. Recruiting first, the newest first:

140 more — sign in →

All 145 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 243 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 834 studies in Uterine Cervical Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a 2-part trial: a Phase 1, open-label, dose-escalation study in participants with metastatic or locally advanced solid tumors, with a consecutive Phase 2 expansion to evaluate efficacy in participants with recurrent, unresectable, or metastatic (advanced) cervical cancer that has progressed after a platinum-based treatment regimen.

Read the detailed description

Phase 1: Dose Escalation

Phase 1 will consist of a standard 3+3 dose escalation with the following escalating dose levels and schedules:

Part A1: 1, 3, and 10 milligrams/kilogram (mg/kg) administered every 2 weeks

Part A2: 6 and 10 mg/kg every 3 weeks

Each participant will stay on the dose level and schedule assigned at trial entry. Participants will receive AGEN2034 for a maximum of 2 years or until confirmed progression, unacceptable toxicity, or any criterion for stopping the study drug or withdrawal from the trial occurs.

A Safety Monitoring Committee (SMC) will assess safety; decide on dose-escalation and opening of backfill enrollment; define the recommended Phase 2 dose (RP2D); and determine opening of the Phase 2 cohorts.

In Part A1, the first participant of each cohort will be observed for 16 days (that is, ≥48 hours after second dose) for occurrence of dose-limiting toxicity (DLT) before the second participant is administered trial medication. Thereafter, within each cohort, consecutively enrolled participants may initiate treatment ≥48 hours after the prior enrolled participant-initiated treatment. Dose escalation will continue until the maximum tolerated dose (MTD) is reached or the maximum planned dose level (10.0 mg/kg) is shown to be safe. The MTD is defined as the dose below which ≥2 DLTs are observed.

Once Part A1 is completed, enrollment to Part A2 will begin. If \<2 DLTs are observed in Part A1 at the maximum planned dose of 10 mg/kg every 2 weeks, open enrollment to Part A2 will begin with enrollment of 10 participants at 6 mg/kg every 3 weeks, followed by open enrollment of 10 participants at 10 mg/kg every 3 weeks. If ≥2 DLTs are observed in Part A1, at the maximum planned dose in Part A1, the standard 3+3 dose escalation will resume with Part A2 where consecutively enrolled participants in dose escalation may initiate treatment ≥48 hours after the prior enrolled participant-initiated treatment.

For cohorts in dose escalation, concurrent with the 3+3 dose escalation schema, additional participants will be backfilled to lower dose levels to ensure that each cohort enrolls a total of 10 participants. Participants enrolled to backfill cohorts may be enrolled simultaneously, without sequential dosing (that is, not required to wait 48 hours between 2 participants). These additional participants at each dose level will have the purpose of generating additional safety, pharmacokinetics, and receptor occupancy data, and will not undergo formal DLT observation.

Phase 2: Dose Expansion

To further characterize safety and efficacy, participants with recurrent, unresectable, or metastatic cervical cancer will be enrolled in Phase 2 and receive the RP2D of AGEN2034 (3 mg/kg every 2 weeks) for a maximum of 2 years or until confirmed progression, unacceptable toxicity, or any criterion for stopping the study drug or withdrawal from the trial occurs.

An SMC will assess safety, and an Independent Data Monitoring Committee will evaluate safety and efficacy.

03

Conditions studied

  • Advanced Cancer
  • Cervical Cancer

Keywords

  • Antibodies
  • Immunologic effects
  • Physiological Effects of Drugs
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily agree to participate by giving written . Participation in pharmacogenomics testing is optional.
  2. Be ≥18 years of age.
  3. Diagnosis and prior systemic treatment:

    1. Phase 1: Have a or cytologically confirmed diagnosis of a or locally advanced solid tumor for which no standard therapy is available or standard therapy has failed.
    2. Phase 2: I. Have (1) a histologically or cytologically confirmed diagnosis of squamous-cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix, and (2) metastatic, locally advanced, and/or unresectable disease at the time of enrollment. Histologic confirmation of the original primary tumor is required via pathology report. Note: The following cervical tumors are not eligible: minimal deviation/adenoma malignum, gastric type adenocarcinoma, clear cell carcinoma, and mesonephric carcinoma. II. Has cervical cancer and has after a platinum-based treatment () regimen for advanced (recurrent, unresectable, or metastatic) disease; Note: Participants who have received >1 prior systemic treatment regimen for their advanced or metastatic disease will be eligible in the following cases: Participant receiving chemotherapy concurrently with primary radiation (for example, weekly cisplatin) or participant receiving chemotherapy following completion of radiation therapy (for example, paclitaxel and carboplatin for ≤4 cycles) and progressed within 6 months after treatment completion.
  4. - based on investigator assessment

    1. Phase 1: Have objective evidence of disease; the presence of measurable disease is not required.
    2. Phase 2: Have measurable disease on imaging based on version 1.1 (RECIST 1.1). Note: Participants must have at least one "target lesion" to be used to assess response, as defined by RECIST 1.1. Tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented or a is obtained to confirm persistence at least 90 days following completion of radiation therapy. Note: Measurable disease by RECIST 1.1 must be confirmed by independent central radiologic review prior to first dose. Participants without centrally confirmed measurable disease at baseline will not be eligible for this trial.
  5. Have a of at least 3 months and an performance status of 0 or 1.
  6. Have adequate organ function as indicated by the following laboratory values:

    1. Adequate hematological function defined by ≥1.5 x 10\^9/liter (L), count ≥100 x 10\^9/L, and stable ≥8 grams/deciliter (without transfusions within 1 week before first dose).
    2. Adequate hepatic function based by a total level ≤ the institutional (IULN), level ≤2.5 x IULN, alanine aminotransferase level ≤2.5 x IULN, and alkaline phosphatase ≤2.5 x IULN.
    3. Adequate renal function defined as creatinine ≤1.5 x IULN or calculated ≥50 milliliters/minute for participants with creatinine levels >1.5 x IULN (if no local guideline is available, creatinine clearance should be calculated using the Cockcroft-Gault Method).
    4. Adequate coagulation defined by or prothrombin time ≤1.5 x IULN (unless the participant is receiving anticoagulant therapy); and activated partial thromboplastin time ≤1.5 x IULN (unless the participant is receiving anticoagulant therapy)
  7. Other than the cancer for which the participant is enrolled, have no history of prior , with the exception of basal cell carcinoma of the skin, superficial bladder cancer, squamous-cell carcinoma of the skin, or has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.
  8. In Phase 2, participants must provide a sufficient and adequate formalin-fixed paraffin-embedded tumor tissue sample preferably from the most recent biopsy of a tumor lesion, collected either at the time of or after the diagnosis of advanced or metastatic disease has been made and from a site not previously irradiated. If no tumor tissue is available, a fresh biopsy will be required.

    Note: Tissue from needle or excisional biopsy or from resection is required.

  9. Female participants must have a negative serum pregnancy test at screening (within 72 hours before first dose of study drug) if of or be of non-childbearing potential. Non-childbearing potential is defined as (by other than medical reasons):

    1. ≥45 years of age and has not menstruated for greater than 1 year,
    2. Amenorrheic for \<2 years without a hysterectomy and oophorectomy and a follicle-stimulating hormone value in the range upon pretrial (screening) evaluation,
    3. Whose status is post hysterectomy, oophorectomy or tubal ligation.
  10. If of childbearing potential, female participants must be willing to use 2 highly effective methods (defined in the informed consent form [ICF]) throughout the study, starting with the screening visit through 120 days after the last dose of study treatment.

    Note: Abstinence is acceptable if this is the established and preferred for the participant.

  11. Male participants with a female partner(s) of childbearing potential must agree to use 2 highly effective methods (defined in the ICF) throughout the trial starting with the screening visit through 120 days after the last dose of study treatment is received. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.

    Note: Abstinence is acceptable if this is the established and preferred contraception for the participant.

  12. Is willing and able to comply with the requirements of the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Is currently participating and receiving study therapy or has participated in a study of an agent and received study therapy or used an investigation device within 4 weeks before the first dose of treatment.
  2. Has an inadequate prior to first dose of study drug defined as:

    1. Received systemic cytotoxic chemotherapy or biological therapy within 3 weeks before first dose,
    2. Received radiation therapy within 3 weeks before first dose, or
    3. Had major surgery within 4 weeks before first dose.
  3. Has received prior therapy with:

    1. Any antibody/drug targeting T-cell co-regulatory proteins (immune checkpoints) such as , anti-programmed cell death ligand 1, or anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibodies
    2. For Phase 2: >1 systemic treatment regimen for the advanced (recurrent, unresectable, or ) cervical cancer for which the participant is considered for the study Note: In Phase 1, prior treatment with a CTLA-4 antibody is permissible for participants with metastatic melanoma.
  4. Has persisting toxicity related to prior therapy of National Cancer Institute version 4.03 (NCI CTCAE) Grade >1 severity.

    Note: Sensory neuropathy or alopecia of Grade ≤2 is acceptable.

  5. Is expected to require any other form of systemic or localized antineoplastic therapy while on trial (including maintenance therapy with another agent, radiation therapy, and/or surgical resection).
  6. Has known severe reactions to fully human monoclonal antibodies (NCI CTCAE Grade ≥3), any history of anaphylaxis, or uncontrolled asthma.
  7. Is receiving systemic ≤7 days prior to the first dose of trial treatment or receiving any other form of systemic medication (corticosteroid use on study for management of immune-related adverse events, and/or a premedication for IV contrast allergies/reactions is allowed). Participants who are receiving daily corticosteroid replacement therapy are an exception to this rule. Examples of permitted therapy are daily prednisone at doses of 5 to 7.5 mg or equivalent hydrocortisone dose, and steroid therapy administered by topical, intraocular, intranasal, and/or inhalation routes.
  8. Has a central nervous system tumor, metastasis(es), and/or carcinomatous meningitis identified either on the baseline brain imaging obtained during the screening period or identified prior to consent. Note: Participants with history of that have been treated may participate provided they show evidence of stable supra-tentorial lesions at screening (based on 2 sets of brain images, performed ≥4 weeks apart, and obtained after the brain metastases treatment). In addition, any neurologic symptoms that developed either as a result of the brain metastases or their treatment must have resolved or be minimal and be expected as sequelae from treated lesions. For individuals who received steroids as part of brain metastases treatment, steroids must be discontinued ≥7 days prior to first dose of study drug.
  9. Has active or history of disease that has required systemic treatment within 2 years of the start of trial treatment (that is, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (that is, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Note: Participants with type 1 diabetes, vitiligo, psoriasis, hypo-, or hyperthyroid disease not requiring immunosuppressive treatment are eligible.
  10. Has had an allogeneic tissue/solid organ transplant.
  11. Has or had interstitial lung disease or has had a history of pneumonitis that has required oral or IV corticosteroids.
  12. Has an active infection requiring intravenous systemic therapy.
  13. Has known history of (HIV) (HIV 1/2 antibodies).
  14. Has known active , or tuberculosis. Active Hepatitis B is defined as a known positive Hepatitis B surface antigen result. Active Hepatitis C is defined by a known positive Hepatitis C antibody result and known quantitative Hepatitis C virus ribonucleic acid results greater than the lower limits of detection of the assay.
  15. Has (that is, active) cardiovascular disease: cerebral vascular accident/stroke or myocardial infarction within 6 months before enrollment, unstable angina, congestive heart failure ( class ≥II), or serious uncontrolled cardiac arrhythmia requiring medication.
  16. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the participant's participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating Investigator.
  17. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  18. Is, at the time of signing , a regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol).
  19. Is legally incapacitated or has limited legal capacity.
  20. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of study treatment.
Terms in these criteria, in plain language(37)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
211 participants (actual)

Study arms

  • Experimental
    Monotherapy

    Dose of 3 mg/kg intravenous (IV) every 2 weeks for up to 24 months.

    Drug: AGEN2034

Interventions

  • Anti-programmed cell death protein-1 (PD-1) Monoclonal Antibody

    Also known as: Anti-PD-1

06

What researchers measure

Primary outcomes

  1. Phase 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) for Balstilimab

    A DLT was defined as any treatment-related toxicity that was National Cancer Institute Common Terminology Criteria for Adverse Event Grade ≥3, confirmed by the safety monitoring committee to be relevant for the study drug treatment, and that occurred during the first 3 weeks of balstilimab treatment in the dose escalation portion of the study (DLT evaluation period).

    Time frame: 21 days

  2. Phase 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which did not necessarily have a causal relationship with the treatment. TEAEs were AEs with onset dates during the on-treatment period, or the worsening of an event during the on-treatment period. A summary of all Serious Adverse Events and Other Adverse Events (nonserious), regardless of causality, is located in the 'Reported Adverse Events' Section.

    Time frame: Up to 3 years

  3. Phase 2: Objective Response Rate (ORR) as Determined by an Independent Endpoint Review Committee (IERC)

    ORR was defined as percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR), as determined by an IERC per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). BOR was defined as the best response recorded from the start of the study treatment until the end of treatment. CR was defined as disappearance of all target lesions, and PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Up to 3 years

Secondary outcomes

  1. Phase 1: Receptor Occupancy of Circulating T Cells

    The percentage of PD-1 receptor occupancy on circulating T cells was measured as an indication of target engagement. An increase in percent occupancy indicates a potential increase in drug effectiveness.

    Time frame: 4 hours after the first dose (Cycle 1 Day 1) and immediately prior to the second dose (Cycle 2 Day 1) (2-3 weeks/cycle)

  2. Phase 1: Maximum Observed Concentration (Cmax) of Balstilimab

    Blood samples were collected for serum balstilimab concentration determinations. Results are reported as micrograms/milliliter (ug/mL).

    Time frame: Day 1 (Pre-dose up to 24 hours post dose) of Cycle 1 and Cycle 2 (2-3 weeks/cycle) (up to 3 weeks)

  3. Phase 1: Area Under the Drug Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) of Balstilimab

    Blood samples were collected for serum balstilimab concentration determinations. Results are reported as hours\*micrograms/milliliter (h\*µg/mL).

    Time frame: Day 1 (Pre-dose up to 24 hours post dose) of Cycle 1 and Cycle 2 (2-3 weeks/cycle) (up to 3 weeks)

  4. Phase 1: Number of Participants With Serum Anti-drug Antibodies (ADAs) for Balstilimab

    Blood samples were collected for serum balstilimab ADA determination.

    Time frame: Up to 2.5 years

  5. Phase 2: Number of Participants Experiencing TEAEs

    An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which did not necessarily have a causal relationship with the treatment. TEAEs were AEs with onset dates during the on-treatment period, or the worsening of an event during the on-treatment period. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Up to 3 years

  6. Phase 2: Cmax of Balstilimab

    Blood samples were collected for serum balstilimab concentration determinations. Results are reported in μg/mL.

    Time frame: Day 1 (Pre-dose up to 24 hours post dose) of Cycle 1 and Cycle 2 (2 weeks/cycle) (up to 2 weeks)

  7. Phase 2: AUC0-last of Balstilimab

    Blood samples were collected for serum balstilimab concentration determinations. Results are reported in day\*μg/mL.

    Time frame: Day 1 (Pre-dose up to 24 hours post dose) of Cycle 1 and Cycle 2 (2 weeks/cycle) (up to 2 weeks)

  8. Phase 2: Number of Participants With Serum ADAs for Balstilimab

    Blood samples were collected for serum balstilimab ADA determination.

    Time frame: Up to 2.5 years

  9. Phase 2: ORR as Determined by the Investigator

    ORR was defined as percentage of participants with a BOR of CR or PR, as determined by the investigator per RECIST 1.1. BOR was defined as the best response recorded from the start of the study treatment until the end of treatment. CR was defined as disappearance of all target lesions, and PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Up to 3 years

  10. Phase 2: Duration of Response (DOR)

    DOR was defined as time from first observation of response to first observation of documented progressive disease (PD) (or death within 12 weeks after last tumor assessment), per RECIST 1.1 and as determined by an IERC and the investigator. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study). Participants without an event at analysis cutoff date were censored on date of last tumor assessment.

    Time frame: Up to 3 years

  11. Phase 2: Disease Control Rate (DCR) as Determined by an IERC

    DCR was defined as the percentage of participants with CR, PR, or stable disease (SD) for at least 12 weeks. CR was defined as disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study).

    Time frame: Up to 3 years

  12. Phase 2: Tumor Control Rate (TCR) as Determined by an IERC

    TCR was defined as percentage of participants who had a BOR of either SD or a confirmed objective response (CR or PR). CR was defined as disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study).

    Time frame: Up to 3 years

  13. Phase 2: Time to Response (TTR) as Determined by an IERC

    TTR was defined as the time from the first dose date to first observation of confirmed response.

    Time frame: Up to 3 years

  14. Phase 2: Progression-free Survival (PFS)

    PFS was defined as time from first treatment administration to first observation of documented PD (or death within 12 weeks after last tumor assessment), per RECIST 1.1, as determined by an IERC and investigator. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study). Participants without an event at analysis cutoff date were censored on date of last tumor assessment.

    Time frame: Up to 3 years

  15. Phase 2: Overall Survival (OS)

    OS was defined as time from start of treatment to death. For participants who were still alive at the time of data cutoff for trial analysis or who were lost to follow-up, survival was censored at the last recorded date that the participant was known to have been alive as of the cutoff date for analysis.

    Time frame: Up to 3 years

07

Results

Posted Jul 30, 2025

Participant flow

Phase 1: Dose Escalation
Participant flow — Phase 1: Dose Escalation
MilestonePhase 1: Balstilimab Dose 1Phase 1: Balstilimab Dose 2Phase 1: Balstilimab Dose 3Phase 1: Balstilimab Dose 4Phase 1: Balstilimab Dose 5Phase 2: Balstilimab Recommended Phase 2 Dose
Started10101010100
Received at least 1 dose of study drug10101010100
Completed002000
Not completed1010810100
Withdrew: Withdrawal by subject224840
Withdrew: Physician decision002100
Withdrew: Death630110
Withdrew: Completed follow up221020
Withdrew: Lost to follow-up011000
Withdrew: Progressive disease000010
Withdrew: Disease progression020000
Withdrew: Protocol violation000020
Phase 2: Dose Expansion
Participant flow — Phase 2: Dose Expansion
MilestonePhase 1: Balstilimab Dose 1Phase 1: Balstilimab Dose 2Phase 1: Balstilimab Dose 3Phase 1: Balstilimab Dose 4Phase 1: Balstilimab Dose 5Phase 2: Balstilimab Recommended Phase 2 Dose
Started00000161
Received at least 1 dose of study drug00000161
Completed0000028
Not completed00000133
Withdrew: Withdrawal by subject000006
Withdrew: Death00000107
Withdrew: Participant left to participate in another trial000001
Withdrew: Administrative study closure0000013
Withdrew: Lost to follow-up000005
Withdrew: Progressive disease000001

Outcome measures

PrimaryPhase 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) for Balstilimab

A DLT was defined as any treatment-related toxicity that was National Cancer Institute Common Terminology Criteria for Adverse Event Grade ≥3, confirmed by the safety monitoring committee to be relevant for the study drug treatment, and that occurred during the first 3 weeks of balstilimab treatment in the dose escalation portion of the study (DLT evaluation period).

Time frame:
21 days
Reported as:
Count of participants · Participants
Phase 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) for Balstilimab
ParticipantsPhase 1: Balstilimab Dose 1Phase 1: Balstilimab Dose 2Phase 1: Balstilimab Dose 3Phase 1: Balstilimab Dose 4Phase 1: Balstilimab Dose 5
Phase 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) for Balstilimab00000
PrimaryPhase 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which did not necessarily have a causal relationship with the treatment. TEAEs were AEs with onset dates during the on-treatment period, or the worsening of an event during the on-treatment period. A summary of all Serious Adverse Events and Other Adverse Events (nonserious), regardless of causality, is located in the 'Reported Adverse Events' Section.

Time frame:
Up to 3 years
Reported as:
Count of participants · Participants
Phase 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
ParticipantsPhase 1: Balstilimab Dose 1Phase 1: Balstilimab Dose 2Phase 1: Balstilimab Dose 3Phase 1: Balstilimab Dose 4Phase 1: Balstilimab Dose 5
Phase 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)1010101010
PrimaryPhase 2: Objective Response Rate (ORR) as Determined by an Independent Endpoint Review Committee (IERC)

ORR was defined as percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR), as determined by an IERC per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). BOR was defined as the best response recorded from the start of the study treatment until the end of treatment. CR was defined as disappearance of all target lesions, and PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Up to 3 years
Reported as:
Number · percentage of participants
Phase 2: Objective Response Rate (ORR) as Determined by an Independent Endpoint Review Committee (IERC)
percentage of participantsPhase 2: Balstilimab Recommended Phase 2 Dose
Phase 2: Objective Response Rate (ORR) as Determined by an Independent Endpoint Review Committee (IERC)15.6 (10.8 to 22.0)
SecondaryPhase 1: Receptor Occupancy of Circulating T Cells

The percentage of PD-1 receptor occupancy on circulating T cells was measured as an indication of target engagement. An increase in percent occupancy indicates a potential increase in drug effectiveness.

Time frame:
4 hours after the first dose (Cycle 1 Day 1) and immediately prior to the second dose (Cycle 2 Day 1) (2-3 weeks/cycle)
Reported as:
Mean · percent occupancy
Phase 1: Receptor Occupancy of Circulating T Cells
percent occupancyPhase 1: Balstilimab Dose 1Phase 1: Balstilimab Dose 2Phase 1: Balstilimab Dose 3Phase 1: Balstilimab Dose 4Phase 1: Balstilimab Dose 5
Cycle 1 Day 173.2 ± 11.9569.4 ± 5.52—76.6 ± 2.95—
Cycle 2 Day 167.7 ± 16.9361.6 ± 1.70—72.1 ± 8.29—
SecondaryPhase 1: Maximum Observed Concentration (Cmax) of Balstilimab

Blood samples were collected for serum balstilimab concentration determinations. Results are reported as micrograms/milliliter (ug/mL).

Time frame:
Day 1 (Pre-dose up to 24 hours post dose) of Cycle 1 and Cycle 2 (2-3 weeks/cycle) (up to 3 weeks)
Reported as:
Geometric mean · ug/mL
Phase 1: Maximum Observed Concentration (Cmax) of Balstilimab
ug/mLPhase 1: Balstilimab Dose 1Phase 1: Balstilimab Dose 2Phase 1: Balstilimab Dose 3Phase 1: Balstilimab Dose 4Phase 1: Balstilimab Dose 5
Cycle 1 Day 118.1 ± 34.371.9 ± 19.5153 ± 23.7236 ± 26.6282 ± 28.4
Cycle 2 Day 120.3 ± 47.086.3 ± 30.0161 ± 27.5239 ± 28.2315 ± 25.5
SecondaryPhase 1: Area Under the Drug Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) of Balstilimab

Blood samples were collected for serum balstilimab concentration determinations. Results are reported as hours\*micrograms/milliliter (h\*µg/mL).

Time frame:
Day 1 (Pre-dose up to 24 hours post dose) of Cycle 1 and Cycle 2 (2-3 weeks/cycle) (up to 3 weeks)
Reported as:
Geometric mean · h*µg/mL
Phase 1: Area Under the Drug Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) of Balstilimab
h*µg/mLPhase 1: Balstilimab Dose 1Phase 1: Balstilimab Dose 2Phase 1: Balstilimab Dose 3Phase 1: Balstilimab Dose 4Phase 1: Balstilimab Dose 5
Cycle 1 Day 11265 ± 47.46470 ± 34.612632 ± 51.522294 ± 47.530751 ± 50.4
Cycle 2 Day 11477 ± 73.77725 ± 40.217479 ± 49.421298 ± 47.142266 ± 41.0
SecondaryPhase 1: Number of Participants With Serum Anti-drug Antibodies (ADAs) for Balstilimab

Blood samples were collected for serum balstilimab ADA determination.

Time frame:
Up to 2.5 years
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With Serum Anti-drug Antibodies (ADAs) for Balstilimab
ParticipantsPhase 1: Balstilimab Dose 1Phase 1: Balstilimab Dose 2Phase 1: Balstilimab Dose 3Phase 1: Balstilimab Dose 4Phase 1: Balstilimab Dose 5
Phase 1: Number of Participants With Serum Anti-drug Antibodies (ADAs) for Balstilimab30000
SecondaryPhase 2: Number of Participants Experiencing TEAEs

An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which did not necessarily have a causal relationship with the treatment. TEAEs were AEs with onset dates during the on-treatment period, or the worsening of an event during the on-treatment period. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Up to 3 years
Reported as:
Count of participants · Participants
Phase 2: Number of Participants Experiencing TEAEs
ParticipantsPhase 2: Balstilimab Recommended Phase 2 Dose
Phase 2: Number of Participants Experiencing TEAEs161
SecondaryPhase 2: Cmax of Balstilimab

Blood samples were collected for serum balstilimab concentration determinations. Results are reported in μg/mL.

Time frame:
Day 1 (Pre-dose up to 24 hours post dose) of Cycle 1 and Cycle 2 (2 weeks/cycle) (up to 2 weeks)
Reported as:
Geometric mean · μg/mL
Phase 2: Cmax of Balstilimab
μg/mLPhase 2: Balstilimab Recommended Phase 2 Dose
Cycle 1 Day 155.4 ± 42.8
Cycle 2 Day 156.6 ± 23.9
SecondaryPhase 2: AUC0-last of Balstilimab

Blood samples were collected for serum balstilimab concentration determinations. Results are reported in day\*μg/mL.

Time frame:
Day 1 (Pre-dose up to 24 hours post dose) of Cycle 1 and Cycle 2 (2 weeks/cycle) (up to 2 weeks)
Reported as:
Geometric mean · day*μg/mL
Phase 2: AUC0-last of Balstilimab
day*μg/mLPhase 2: Balstilimab Recommended Phase 2 Dose
Cycle 1 Day 1174 ± 46.3
Cycle 2 Day 1184 ± 59.7
SecondaryPhase 2: Number of Participants With Serum ADAs for Balstilimab

Blood samples were collected for serum balstilimab ADA determination.

Time frame:
Up to 2.5 years
Reported as:
Count of participants · Participants
Phase 2: Number of Participants With Serum ADAs for Balstilimab
ParticipantsPhase 2: Balstilimab Recommended Phase 2 Dose
Phase 2: Number of Participants With Serum ADAs for Balstilimab7
SecondaryPhase 2: ORR as Determined by the Investigator

ORR was defined as percentage of participants with a BOR of CR or PR, as determined by the investigator per RECIST 1.1. BOR was defined as the best response recorded from the start of the study treatment until the end of treatment. CR was defined as disappearance of all target lesions, and PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Up to 3 years
Reported as:
Number · percentage of participants
Phase 2: ORR as Determined by the Investigator
percentage of participantsPhase 2: Balstilimab Recommended Phase 2 Dose
Phase 2: ORR as Determined by the Investigator14.4 (9.8 to 20.6)
SecondaryPhase 2: Duration of Response (DOR)

DOR was defined as time from first observation of response to first observation of documented progressive disease (PD) (or death within 12 weeks after last tumor assessment), per RECIST 1.1 and as determined by an IERC and the investigator. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study). Participants without an event at analysis cutoff date were censored on date of last tumor assessment.

Time frame:
Up to 3 years
Reported as:
Median · months
Phase 2: Duration of Response (DOR)
monthsPhase 2: Balstilimab Recommended Phase 2 Dose
IERCNA (7.3 to NA)
InvestigatorNA (8.9 to NA)
SecondaryPhase 2: Disease Control Rate (DCR) as Determined by an IERC

DCR was defined as the percentage of participants with CR, PR, or stable disease (SD) for at least 12 weeks. CR was defined as disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study).

Time frame:
Up to 3 years
Reported as:
Number · percentage of participants
Phase 2: Disease Control Rate (DCR) as Determined by an IERC
percentage of participantsPhase 2: Balstilimab Recommended Phase 2 Dose
Phase 2: Disease Control Rate (DCR) as Determined by an IERC50.6 (43.0 to 58.3)
SecondaryPhase 2: Tumor Control Rate (TCR) as Determined by an IERC

TCR was defined as percentage of participants who had a BOR of either SD or a confirmed objective response (CR or PR). CR was defined as disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study).

Time frame:
Up to 3 years
Reported as:
Number · percentage of participants
Phase 2: Tumor Control Rate (TCR) as Determined by an IERC
percentage of participantsPhase 2: Balstilimab Recommended Phase 2 Dose
Phase 2: Tumor Control Rate (TCR) as Determined by an IERC52.5 (44.8 to 60.1)
SecondaryPhase 2: Time to Response (TTR) as Determined by an IERC

TTR was defined as the time from the first dose date to first observation of confirmed response.

Time frame:
Up to 3 years
Reported as:
Median · days
Phase 2: Time to Response (TTR) as Determined by an IERC
daysPhase 2: Balstilimab Recommended Phase 2 Dose
Phase 2: Time to Response (TTR) as Determined by an IERC82.0 (60.5 to 108.4)
SecondaryPhase 2: Progression-free Survival (PFS)

PFS was defined as time from first treatment administration to first observation of documented PD (or death within 12 weeks after last tumor assessment), per RECIST 1.1, as determined by an IERC and investigator. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study). Participants without an event at analysis cutoff date were censored on date of last tumor assessment.

Time frame:
Up to 3 years
Reported as:
Median · months
Phase 2: Progression-free Survival (PFS)
monthsPhase 2: Balstilimab Recommended Phase 2 Dose
IERC2.8 (2.4 to 3.9)
Investigator3.6 (2.7 to 4.2)
SecondaryPhase 2: Overall Survival (OS)

OS was defined as time from start of treatment to death. For participants who were still alive at the time of data cutoff for trial analysis or who were lost to follow-up, survival was censored at the last recorded date that the participant was known to have been alive as of the cutoff date for analysis.

Time frame:
Up to 3 years
Reported as:
Median · months
Phase 2: Overall Survival (OS)
monthsPhase 2: Balstilimab Recommended Phase 2 Dose
Phase 2: Overall Survival (OS)11.2 (9.5 to 14.5)

Adverse events

Collected over From Day 1 to the end of study (3 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: Balstilimab Dose 16/10 (60%)5/10 (50%)10/10 (100%)
Phase 1: Balstilimab Dose 23/10 (30%)3/10 (30%)10/10 (100%)
Phase 1: Balstilimab Dose 30/10 (0%)5/10 (50%)10/10 (100%)
Phase 1: Balstilimab Dose 41/10 (10%)3/10 (30%)10/10 (100%)
Phase 1: Balstilimab Dose 51/10 (10%)2/10 (20%)10/10 (100%)
Phase 2: Balstilimab Recommended Phase 2 Dose108/161 (67.1%)90/161 (55.9%)158/161 (98.1%)
Most frequent serious events
Showing 10 of 105
Most frequent serious events
EventPhase 1: Balstilimab Dose 1Phase 1: Balstilimab Dose 2Phase 1: Balstilimab Dose 3Phase 1: Balstilimab Dose 4Phase 1: Balstilimab Dose 5Phase 2: Balstilimab Recommended Phase 2 Dose
Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/100/100/100/101/102/161
Metastases to spineNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/100/100/100/101/100/161
Tumour associated feverNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/100/100/101/100/101/161
Hypertensive crisisVascular disorders0/100/101/100/100/100/161
PneumonitisRespiratory, thoracic and mediastinal disorders1/101/100/100/100/101/161
Pleural effusionRespiratory, thoracic and mediastinal disorders0/100/100/100/101/100/161
Confusional statePsychiatric disorders0/101/100/100/100/100/161
Cardiopulmonary failureCardiac disorders1/100/100/100/100/100/161
Ischaemic strokeNervous system disorders0/100/101/100/100/100/161
ColitisGastrointestinal disorders0/100/101/100/100/101/161
Most frequent other events
Showing 10 of 177
Most frequent other events
EventPhase 1: Balstilimab Dose 1Phase 1: Balstilimab Dose 2Phase 1: Balstilimab Dose 3Phase 1: Balstilimab Dose 4Phase 1: Balstilimab Dose 5Phase 2: Balstilimab Recommended Phase 2 Dose
Erectile dysfunctionReproductive system and breast disorders0/21/20/11/10/2—
FatigueGeneral disorders7/104/103/107/103/1037/161
AnaemiaBlood and lymphatic system disorders7/104/103/103/103/1080/161
NauseaGastrointestinal disorders6/103/104/105/103/1047/161
VomitingGastrointestinal disorders3/103/102/105/101/1038/161
Decreased appetiteMetabolism and nutrition disorders3/105/103/105/102/1034/161
ConstipationGastrointestinal disorders4/102/102/101/101/1045/161
DiarrhoeaGastrointestinal disorders3/104/102/103/102/1041/161
DyspnoeaRespiratory, thoracic and mediastinal disorders4/103/101/100/102/1023/161
Nasal congestionRespiratory, thoracic and mediastinal disorders0/101/100/104/102/103/161

Baseline characteristics

Safety Analysis Set: all participants who received at least 1 dose of balstilimab.

Age, Customized
Age, Customized(Participants)Phase 1: Balstilimab Dose 1Phase 1: Balstilimab Dose 2Phase 1: Balstilimab Dose 3Phase 1: Balstilimab Dose 4Phase 1: Balstilimab Dose 5Phase 2: Balstilimab Recommended Phase 2 DoseTotal
Adults (18-64 years)79676119154
From 65-84 years314344257
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: Balstilimab Dose 1Phase 1: Balstilimab Dose 2Phase 1: Balstilimab Dose 3Phase 1: Balstilimab Dose 4Phase 1: Balstilimab Dose 5Phase 2: Balstilimab Recommended Phase 2 DoseTotal
Female88998161203
Male2211208
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1: Balstilimab Dose 1Phase 1: Balstilimab Dose 2Phase 1: Balstilimab Dose 3Phase 1: Balstilimab Dose 4Phase 1: Balstilimab Dose 5Phase 2: Balstilimab Recommended Phase 2 DoseTotal
Hispanic or Latino102113843
Not Hispanic or Latino9108993984
Unknown or Not Reported000008484
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase 1: Balstilimab Dose 1Phase 1: Balstilimab Dose 2Phase 1: Balstilimab Dose 3Phase 1: Balstilimab Dose 4Phase 1: Balstilimab Dose 5Phase 2: Balstilimab Recommended Phase 2 DoseTotal
Asian0311117
Black or African American2100025
White8699972113
Not Reported (France)000008181
Romanian0000011
Mixed0000033
Brown0000011
08

Study locations

44 sites
  • HonorHealth Research Institute
    Scottsdale, Arizona 85258, United States
  • City of Hope
    Duarte, California 91010, United States
  • University of Southern California - Keck School of Medicine
    Los Angeles, California 90033, United States
  • Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Florida Cancer Specialists & Research Institute
    Sarasota, Florida 34232, United States
  • Augusta Oncology
    Augusta, Georgia 30912, United States
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
    Chicago, Illinois 60611, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • The Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
  • The University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Swedish Medical Center-Cherry Hill Campus
    Seattle, Washington 98104, United States
  • Pindara Private Hospital
    Benowa, Queensland 4217, Australia
  • Calvary North Adelaide Hospital
    North Adelaide, South Australia 5006, Australia
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
  • IMIP
    Recife, Pernambuco 50070-550, Brazil
  • Instituto Nacional de Câncer
    Rio de Janeiro, Rio de Janeiro 20220-410, Brazil
  • Hospital de Caridade de Ijuí
    Ijuí, Rio Grande do Sul 98700-000, Brazil
  • Hospital Mãe de Deus
    Porto Alegre, Rio Grande do Sul 90110-270, Brazil
  • Instituto do Cancer do Estado de São Paulo
    São Paulo, São Paulo 01246-000, Brazil
  • Hospital Amaral Carvalho
    São Paulo, São Paulo 03162-065, Brazil
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto
    São José do Rio Preto, 15090-000, Brazil
  • Centro Oncológico del Norte
    Antofagasta, AN 1240000, Chile
  • Centro De Investigación Del Cancer James Lind
    Temuco, AR 4800827, Chile
  • Fundación Arturo López Pérez
    Santiago, RM 7500918, Chile
  • Bradford Hill
    Santiago, RM 8420323, Chile
  • East-Tallinn Central Hospital
    Tallinn, 1131, Estonia
  • North Estonia Medical Centre Foundation
    Tallinn, 13419, Estonia
  • Institut Bergonié
    Bordeaux, 33076, France
  • Centre Léon Bérard
    Lyon, 69008, France
  • L'Institut Paoli - Calmettes
    Marseille, 13273, France
  • CHU Hôpital de la Timone
    Marseille, 13385, France
  • Centre Antoine-Lacassagne
    Nice, 6189, France
  • Hôpital Cochin
    Paris, 75014, France
  • Groupe Hospitalier Diaconesses Croix Saint-Simon - Hopital de la Croix Saint-Simon
    Paris, 75020, France
  • Clinique Armoricaine de Radiologie
    Plérin, 22190, France
  • Institute de Cancerologie de l'Ouest (ICO) - René Gauducheau
    Saint-Herblain, 44805, France
  • Institut Claudius Regaud
    Toulouse, 31100, France
  • Gustave Roussy
    Villejuif, 94800, France
  • Szpital Swietego Rafala w Krakowie
    Krakow, Lesser Poland Voivodeship 30-693, Poland
  • Szpitale Pomorskie Sp. z o.o.
    Gdynia, Pomeranian Voivodeship 81-519, Poland
  • Vall d'Hebron Institut d'Oncologia
    Barcelona, 8035, Spain
  • Hospital Clínic de Barcelona
    Barcelona, 8036, Spain
  • Clínica Universidad de Navarra
    Madrid, 28027, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Jun 2022, 62 months.

Results were first posted in Jul 2025, 3 years 1 month after primary completion. A results delay was requested in Jun 2023.

Of 53 industry-sponsored phase 1/2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 75. This study's 62 months is close to that.

Counting every sponsor, half of 81 studies reached it within 62 months; a quarter within 36 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2017
First posted
Apr 7, 2017
StartActual
Apr 11, 2017
Primary completionActual
Jun 15, 2022
CompletionActual
Jun 15, 2022
Results delay requested
Jun 1, 2023
Results first posted
Jul 30, 2025
Last update
Jul 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03104699
Lead sponsor
Agenus Inc.
Responsible party
Sponsor
First posted
Apr 7, 2017
Start date
Apr 11, 2017
Primary completion
Jun 15, 2022
Completion
Jun 15, 2022
Results posted
Jul 30, 2025
Last update
Jul 30, 2025

Study contacts

Medical Director
study director · Agenus Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Balstilimab

Start the discussion